An FDA advisory panel votes 13-2 to recommend that the agency approve Aegerion's (AEGR +5%)...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

An FDA advisory panel votes 13-2 to recommend that the agency approve Aegerion's (AEGR +5%) lomitapide drug for treating very high cholestoral in patients with a rare genetic disease called homozygous familial hypercholesterolemia, which can lead to early death. The FDA is due to decide by the end of December.  (PR)